News Releases

Date Title and Summary Additional Formats
Toggle Summary AVI BioPharma Initiates NEUGENE Antisense Clinical Program in Coronary Artery Bypass Grafting
PORTLAND, Ore.--(BUSINESS WIRE)--Oct. 18, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), today announced the initiation of a clinical program to assess the safety and effectiveness of AVI-5126, a new generation of NEUGENE(R) antisense drug for treating coronary vascular disease.
View HTML
Toggle Summary AVI BioPharma Reports Results on Hepatitis C Virus Clinical Trial
PORTLAND, Ore.--(BUSINESS WIRE)--Oct. 4, 2006--AVI BioPharma, Inc. (Nasdaq:AVII) reported results today from the second phase of its multicenter study in patients with chronic active hepatitis C virus (HCV) infection. The second phase of this exploratory trial was designed to assess the safety,
View HTML
Toggle Summary AVI BioPharma Presents Positive Preclinical Data Evaluating NEUGENE Antisense Compounds Against Influenza A Virus and the E. coli Bacteria
Business Editors/Biotech Writers BIOWIRE2K ICAAC 2006 PORTLAND, Ore.--(BUSINESS WIRE)--Sept. 29, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), today presented preclinical data regarding the use of its NEUGENE(R) antisense technology against influenza A and E. coli infection.
View HTML
Toggle Summary AVI BioPharma to Present at UBS Global Life Sciences Conference
PORTLAND, Ore.--(BUSINESS WIRE)--Sept. 27, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), today announced that on Wednesday, Sept. 27, 2006, Alan P. Timmins, AVI's president and COO, will present the company's overall strategy and progress to date at the UBS Global Life Sciences Conference to be held at
View HTML
Toggle Summary AVI BioPharma Incorporated 2006 Second Quarter Financial Results Conference Call Transcript
Moderator: Denis Burger August 8, 2006 8:00 a.m. Pacific Time Operator: Welcome to the AVI BioPharma 2006 Second Quarter Financial Results conference call. At this time, all participants are in a listen–only mode. Following management’s prepared remarks, we’ll hold a Q&A session.
View HTML
Toggle Summary AVI BioPharma Announces Publication of Positive Results from New Class of Antibiotics Using NEUGENE Antisense Technology
PORTLAND, Ore., Aug 09, 2006 (BUSINESS WIRE) -- AVI BioPharma, Inc. (Nasdaq:AVII) today announced the publication of positive preclinical results from a new class of antisense-based antibiotics, called NeuBiotics. The article, titled "Gene-Specific Effects of Antisense Phosphorodiamidate Morpholino
View HTML
Toggle Summary AVI BioPharma Reports Second Quarter Financial Results; Conference Call Begins Today at 11:00 a.m. Eastern Time
PORTLAND, Ore.--(BUSINESS WIRE)--Aug. 8, 2006--AVI BioPharma, Inc. (Nasdaq:AVII) today reported financial results for the three and six months ended June 30, 2006. The net loss for the second quarter of 2006 was $6.9 million, or $0.13 per share, compared with a net loss for the second quarter of
View HTML
Toggle Summary AVI BioPharma Provides Cardiovascular Program Update; Notice of Allowance of Two Patents Strengthens Cardiovascular Restenosis Program
PORTLAND, Ore.--(BUSINESS WIRE)--Aug. 3, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), today issued an update on its licensed and internal cardiovascular programs, both of which have been strengthened by notices of allowance from the U.S. Patent Office. AVI licensed its vascular disease program to the
View HTML
Toggle Summary AVI BioPharma Announces 2006 Second Quarter Financial Results Conference Call
PORTLAND, Ore.--(BUSINESS WIRE)--Aug. 1, 2006--AVI BioPharma, Inc. (Nasdaq:AVII) today announced that the company will hold a conference call to discuss its 2006 second quarter financial results on Tuesday, August 8, 2006, at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time).
View HTML
Toggle Summary AVI BioPharma Announces Hepatitis C Virus Clinical Study Modification
PORTLAND, Ore.--(BUSINESS WIRE)--July 20, 2006--AVI BioPharma, Inc. (Nasdaq:AVII) announced today that it has entered patients to fill two new cohorts to extend the duration of treatment with AVI-4065 in its hepatitis C virus (HCV) clinical trial. One cohort will be treated twice daily for 28 days
View HTML

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.

There are no items to display.